Replies to post #213939 on Biotech Values

[DewDiligence]

Re: ABBV-AMGN Humira settlement

The key date is 1/31/23, when ABBV has permitted AMGN to launch Amgevita (Humira FoB) in the US market.

Other Humira-FoB companies such as MNTA will presumably be able to get the same deal, but will they take it?

MNTA’s CEO has asserted that MNTA has a workaround for ABBV’s US Humira patents that pertain to formulation, specifically, which is something that AMGN presumably does not have.

In any case, we probably won’t know for at least a year (when FDA approves MNTA’s M923 Humira FoB) whether MNTA will opt to defend or settle.

p.s. CHRS +3%, MNTA +2% today.

[DewDiligence]

AMGN apparently spent >$200M on legal expenses related to Humira: #msg-137836099.

[DewDiligence]

ABBV settles Humira-patent litigation with Samsung on terms more favorable (to ABBV) than the prior settlement with AMGN:

https://finance.yahoo.com/news/abbvie-announces-global-resolution-humira-120500818.html

Samsung Bioepis can launch its Humira FoB in the US on 6/30/23—five months later than AMGN’s launch date of 1/31/18 (#msg-134976468). I.e. AMGN effectively gained five months of Humira-FoB exclusivity in the US market by being the first to settle with ABBV.

Note: The Humira patents in question pertain to formulation and methods of use, not CoM.